MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
Integra LifeSciences Holdings Corporation Operating Income 2011-2026 | IART
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Integra LifeSciences Holdings Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28.4 M | 112 M | 239 M | 197 M | 151 M | 93.8 M | 111 M | 44.8 M | 115 M | 79.6 M | 67.9 M | 35.4 M | 73.8 M | 54.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 239 M | 28.4 M | 100 M |
Quarterly Operating Income Integra LifeSciences Holdings Corporation
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -513 M | -15.5 M | -8.15 M | -3.03 M | 3.96 M | 26.6 M | 12.5 M | 36.4 M | - | 65 M | 59.9 M | 46.2 M | - | 56.4 M | 51.9 M | 30.7 M | - | 57.5 M | 14.1 M | 27.1 M | - | -20.6 M | 46 M | 32.3 M | - | 23.7 M | 27.6 M | 25.6 M | - | 10.6 M | 17 M | 9.96 M | - | 30.1 M | 22.4 M | 22.1 M | - | 9.99 M | 24.3 M | 21.2 M | - | 17.1 M | 12.4 M | 8.74 M | - | -31.1 M | 5.56 M | -2.19 M | - | 19.7 M | 18 M | 17.5 M | - | 18.3 M | 8 M | 20.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 65 M | -513 M | 8.27 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AxoGen
AXGN
|
-3.29 M | $ 31.63 | 2.03 % | $ 1.4 B |  USA |
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Boston Scientific Corporation
BSX
|
2.6 B | $ 95.41 | 0.76 % | $ 140 B | USA |
 |
Abiomed
ABMD
|
230 M | - | - | $ 17.2 B | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Alphatec Holdings
ATEC
|
-136 M | $ 21.25 | 2.36 % | $ 3.04 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
Apyx Medical Corporation
APYX
|
-17.3 M | $ 3.6 | 2.86 % | $ 125 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
-5.13 M | $ 9.15 | 2.81 % | $ 657 M |  Israel |
 |
Bio-Rad Laboratories
BIO
|
269 M | $ 320.95 | 5.1 % | $ 9.06 B | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
CONMED Corporation
CNMD
|
200 M | $ 42.12 | 3.97 % | $ 1.3 B | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
BioSig Technologies
BSGM
|
-12.9 M | - | 37.08 % | $ 85.7 M | USA |
 |
Bruker Corporation
BRKR
|
253 M | $ 50.6 | 5.18 % | $ 7.54 K | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 3.48 | 2.35 % | $ 130 M |  France |
 |
Abbott Laboratories
ABT
|
6.82 B | $ 126.37 | 1.76 % | $ 220 B | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
-156 M | - | -10.19 % | $ 1.99 M | USA |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
Electromed
ELMD
|
9.66 M | $ 28.03 | 2.34 % | $ 237 M | USA |
 |
Second Sight Medical Products
EYES
|
-24.7 M | - | -0.97 % | $ 54.4 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
InMode Ltd.
INMD
|
113 M | $ 15.27 | 3.18 % | $ 1.21 B | Israel |
 |
IRadimed Corporation
IRMD
|
22 M | $ 98.11 | 2.73 % | $ 1.24 B | USA |
 |
Align Technology
ALGN
|
608 M | $ 160.18 | 2.66 % | $ 12 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-35 M | $ 18.13 | 3.22 % | $ 418 M | USA |
 |
Accuray Incorporated
ARAY
|
7.84 M | $ 0.89 | 4.38 % | $ 91.5 M | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
-19.7 M | $ 14.34 | 2.21 % | $ 388 M | USA |
 |
FONAR Corporation
FONR
|
5.31 M | $ 18.52 | 0.03 % | $ 121 M | USA |
 |
LivaNova PLC
LIVN
|
129 M | $ 63.29 | 4.37 % | $ 3.43 B |  Britain |
|
LENSAR
LNSR
|
-10.7 M | $ 11.32 | -2.5 % | $ 130 M | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
IRIDEX Corporation
IRIX
|
-10 M | $ 1.21 | 3.42 % | $ 19.5 M | USA |
 |
Globus Medical
GMED
|
166 M | $ 90.81 | 4.02 % | $ 12.3 B | USA |
 |
Aziyo Biologics
AZYO
|
-30.5 M | - | 1.37 % | $ 20.5 M | USA |
 |
Establishment Labs Holdings
ESTA
|
-50 M | $ 65.25 | -5.21 % | $ 1.84 B |  Costa-rica |